diff --git a/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md b/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md index 329db7879..fb1a15b80 100644 --- a/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md +++ b/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md @@ -19,22 +19,28 @@ The competitive dynamics (Lilly vs. Novo vs. generics post-2031) will drive pric ### Additional Evidence (extend) -*Source: [[2024-08-01-jmcp-glp1-persistence-adherence-commercial-populations]] | Added: 2026-03-15 | Extractor: anthropic/claude-sonnet-4.5* +*Source: 2024-08-01-jmcp-glp1-persistence-adherence-commercial-populations | Added: 2026-03-15 | Extractor: anthropic/claude-sonnet-4.5* Real-world persistence data from 125,474 commercially insured patients shows the chronic use model fails not because patients choose indefinite use, but because most cannot sustain it: only 32.3% of non-diabetic obesity patients remain on GLP-1s at one year, dropping to approximately 15% at two years. This creates a paradox for payer economics—the "inflationary chronic use" concern assumes sustained adherence, but the actual problem is insufficient persistence. Under capitation, payers pay for 12 months of therapy ($2,940 at $245/month) for patients who discontinue and regain weight, capturing net cost with no downstream savings from avoided complications. The economics only work if adherence is sustained AND the payer captures downstream benefits—with 85% discontinuing by two years, the downstream cardiovascular and metabolic savings that justify the cost never materialize for most patients. ### Additional Evidence (extend) -*Source: [[2025-06-01-cell-med-glp1-societal-implications-obesity]] | Added: 2026-03-15* +*Source: 2025-06-01-cell-med-glp1-societal-implications-obesity | Added: 2026-03-15* The Cell Press review characterizes GLP-1s as marking a 'system-level redefinition' of cardiometabolic management with 'ripple effects across healthcare costs, insurance models, food systems, long-term population health.' Obesity costs the US $400B+ annually, providing context for the scale of potential cost impact. The WHO issued conditional recommendations within 2 years of widespread adoption (December 2025), unusually fast for a major therapeutic category. ### Additional Evidence (extend) -*Source: [[2025-03-01-medicare-prior-authorization-glp1-near-universal]] | Added: 2026-03-15* +*Source: 2025-03-01-medicare-prior-authorization-glp1-near-universal | Added: 2026-03-15* MA plans' near-universal prior authorization creates administrative friction that may worsen the already-poor adherence rates for GLP-1s. PA requirements ensure only T2D-diagnosed patients can access, effectively blocking obesity-only coverage despite FDA approval. This access restriction compounds the chronic-use economics challenge by adding administrative barriers on top of existing adherence problems. + +### Additional Evidence (extend) +*Source: [[2025-12-23-cms-balance-model-glp1-obesity-coverage]] | Added: 2026-03-16* + +CMS is explicitly testing whether combining GLP-1s with lifestyle supports can break the chronic-use inflation model. The BALANCE Model's requirement for evidence-based lifestyle interventions alongside medication addresses the adherence problem by potentially sustaining benefits after discontinuation, converting GLP-1s from chronic-use to intervention-plus-behavior-change model. + --- Relevant Notes: diff --git a/domains/health/glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md b/domains/health/glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md index 1f412e7f8..71f25d07f 100644 --- a/domains/health/glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md +++ b/domains/health/glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md @@ -47,6 +47,12 @@ This data comes from commercially insured populations (younger, fewer comorbidit No data yet on whether payment model affects persistence—does being in an MA plan with care coordination improve adherence vs. fee-for-service? This is directly relevant to value-based care design. + +### Additional Evidence (extend) +*Source: [[2025-12-23-cms-balance-model-glp1-obesity-coverage]] | Added: 2026-03-16* + +The BALANCE Model directly addresses low persistence by mandating lifestyle supports alongside GLP-1 coverage. CMS is testing whether behavioral interventions can sustain metabolic benefits after medication discontinuation, potentially solving the adherence problem that makes GLP-1s inflationary under current coverage models. + --- Relevant Notes: diff --git a/domains/health/value-based care transitions stall at the payment boundary because 60 percent of payments touch value metrics but only 14 percent bear full risk.md b/domains/health/value-based care transitions stall at the payment boundary because 60 percent of payments touch value metrics but only 14 percent bear full risk.md index 80dcb4194..106bbf166 100644 --- a/domains/health/value-based care transitions stall at the payment boundary because 60 percent of payments touch value metrics but only 14 percent bear full risk.md +++ b/domains/health/value-based care transitions stall at the payment boundary because 60 percent of payments touch value metrics but only 14 percent bear full risk.md @@ -19,22 +19,28 @@ The Making Care Primary model's termination in June 2025 (after just 12 months, ### Additional Evidence (extend) -*Source: [[2014-00-00-aspe-pace-effect-costs-nursing-home-mortality]] | Added: 2026-03-10 | Extractor: anthropic/claude-sonnet-4.5* +*Source: 2014-00-00-aspe-pace-effect-costs-nursing-home-mortality | Added: 2026-03-10 | Extractor: anthropic/claude-sonnet-4.5* PACE represents the extreme end of value-based care alignment—100% capitation with full financial risk for a nursing-home-eligible population. The ASPE/HHS evaluation shows that even under complete payment alignment, PACE does not reduce total costs but redistributes them (lower Medicare acute costs in early months, higher Medicaid chronic costs overall). This suggests that the 'payment boundary' stall may not be primarily a problem of insufficient risk-bearing. Rather, the economic case for value-based care may rest on quality/preference improvements rather than cost reduction. PACE's 'stall' is not at the payment boundary—it's at the cost-savings promise. The implication: value-based care may require a different success metric (outcome quality, institutionalization avoidance, mortality reduction) than the current cost-reduction narrative assumes. ### Additional Evidence (extend) -*Source: [[2024-08-01-jmcp-glp1-persistence-adherence-commercial-populations]] | Added: 2026-03-15 | Extractor: anthropic/claude-sonnet-4.5* +*Source: 2024-08-01-jmcp-glp1-persistence-adherence-commercial-populations | Added: 2026-03-15 | Extractor: anthropic/claude-sonnet-4.5* GLP-1 persistence data illustrates why value-based care requires risk alignment: with only 32.3% of non-diabetic obesity patients remaining on GLP-1s at one year (15% at two years), the downstream savings that justify the upfront drug cost never materialize for 85% of patients. Under fee-for-service, the pharmacy benefit pays the cost but doesn't capture the avoided hospitalizations. Under partial risk (upside-only), providers have no incentive to invest in adherence support because they don't bear the cost of discontinuation. Only under full risk (capitation) does the entity paying for the drug also capture the downstream savings—but only if adherence is sustained. This makes GLP-1 economics a test case for whether value-based care can solve the "who pays vs. who benefits" misalignment. ### Additional Evidence (confirm) -*Source: [[2025-03-01-medicare-prior-authorization-glp1-near-universal]] | Added: 2026-03-15* +*Source: 2025-03-01-medicare-prior-authorization-glp1-near-universal | Added: 2026-03-15* Medicare Advantage plans bearing full capitated risk increased GLP-1 prior authorization from <5% to nearly 100% within two years (2023-2025), demonstrating that even full-risk capitation does not automatically align incentives toward prevention when short-term cost pressures dominate. Both BCBS and UnitedHealthcare implemented universal PA despite theoretical alignment under capitation. + +### Additional Evidence (extend) +*Source: [[2025-12-23-cms-balance-model-glp1-obesity-coverage]] | Added: 2026-03-16* + +The BALANCE Model moves beyond touching value metrics to bearing full risk by adjusting capitated payment rates for obesity and increasing government reinsurance. This creates genuine downside exposure for participating plans, testing whether risk-bearing payment can make prevention profitable when combined with comprehensive intervention design. + --- Relevant Notes: diff --git a/entities/internet-finance/metadao.md b/entities/internet-finance/metadao.md index cf50ed009..3669307e5 100644 --- a/entities/internet-finance/metadao.md +++ b/entities/internet-finance/metadao.md @@ -58,13 +58,14 @@ The futarchy governance protocol on Solana. Implements decision markets through - **2024-03-02** — [[metadao-increase-meta-liquidity-dutch-auction]] passed: completed Dutch auction and liquidity provision, moving all protocol-owned liquidity to Meteora 1% fee pool - **2025-01-27** — [[metadao-otc-trade-theia-2]] proposed: Theia offers $500K for 370.370 META at 14% premium with 12-month vesting - **2025-01-30** — [[metadao-otc-trade-theia-2]] passed: Theia acquires 370.370 META tokens for $500,000 USDC -- **2023-11-18** — [[metadao-develop-lst-vote-market]] proposed: first product development proposal requesting 3,000 META to build Votium-style validator bribe platform for MNDE/mSOL holders -- **2023-11-29** — [[metadao-develop-lst-vote-market]] passed: approved LST Vote Market development with projected $10.5M enterprise value addition +- **2023-11-18** — metadao-develop-lst-vote-market proposed: first product development proposal requesting 3,000 META to build Votium-style validator bribe platform for MNDE/mSOL holders +- **2023-11-29** — metadao-develop-lst-vote-market passed: approved LST Vote Market development with projected $10.5M enterprise value addition - **2023-12-03** — Proposed Autocrat v0.1 migration with configurable proposal slots and 3-day default duration - **2023-12-13** — Completed Autocrat v0.1 migration, moving 990,000 META, 10,025 USDC, and 5.5 SOL to new program despite unverifiable build - **2024-01-24** — Proposed AMM program to replace CLOB markets, addressing liquidity fragmentation and state rent costs (Proposal CF9QUBS251FnNGZHLJ4WbB2CVRi5BtqJbCqMi47NX1PG) - **2024-01-29** — AMM proposal passed with 400 META on approval and 800 META on completion budget - **2024-08-31** — Passed proposal to enter services agreement with Organization Technology LLC, creating US entity vehicle for paying contributors with $1.378M annualized burn rate. Entity owns no IP (all owned by MetaDAO LLC) and cannot encumber MetaDAO LLC. Agreement cancellable with 30-day notice or immediately for material breach. +- **2025-Q4** — First profitable quarter with $2.51M protocol fees (54% futarchy AMM, 46% Meteora LP). Launched 6 ICOs raising $18.7M total. Governance proposal volume increased 17.5x to $3.6M from $205K in Q3. Total futarchy ecosystem marketcap reached $219M across 8 active protocols. Raised $10M via futarchy-approved OTC sale of 2M META tokens. Balance sheet equity grew from $4M to $16.5M. ## Key Decisions | Date | Proposal | Proposer | Category | Outcome | |------|----------|----------|----------|---------| diff --git a/inbox/archive/.extraction-debug/2025-12-23-cms-balance-model-glp1-obesity-coverage.json b/inbox/archive/.extraction-debug/2025-12-23-cms-balance-model-glp1-obesity-coverage.json new file mode 100644 index 000000000..a72bc6f6a --- /dev/null +++ b/inbox/archive/.extraction-debug/2025-12-23-cms-balance-model-glp1-obesity-coverage.json @@ -0,0 +1,24 @@ +{ + "rejected_claims": [ + { + "filename": "cms-balance-model-tests-glp-1-plus-lifestyle-support-under-risk-bearing-payment-as-first-federal-prevention-economics-experiment.md", + "issues": [ + "missing_attribution_extractor" + ] + } + ], + "validation_stats": { + "total": 1, + "kept": 0, + "fixed": 1, + "rejected": 1, + "fixes_applied": [ + "cms-balance-model-tests-glp-1-plus-lifestyle-support-under-risk-bearing-payment-as-first-federal-prevention-economics-experiment.md:set_created:2026-03-16" + ], + "rejections": [ + "cms-balance-model-tests-glp-1-plus-lifestyle-support-under-risk-bearing-payment-as-first-federal-prevention-economics-experiment.md:missing_attribution_extractor" + ] + }, + "model": "anthropic/claude-sonnet-4.5", + "date": "2026-03-16" +} \ No newline at end of file diff --git a/inbox/archive/2025-12-23-cms-balance-model-glp1-obesity-coverage.md b/inbox/archive/2025-12-23-cms-balance-model-glp1-obesity-coverage.md index e346c64cd..4e0da2e7f 100644 --- a/inbox/archive/2025-12-23-cms-balance-model-glp1-obesity-coverage.md +++ b/inbox/archive/2025-12-23-cms-balance-model-glp1-obesity-coverage.md @@ -7,9 +7,13 @@ date: 2025-12-23 domain: health secondary_domains: [internet-finance] format: policy -status: unprocessed +status: enrichment priority: high tags: [glp-1, cms, balance-model, medicare, medicaid, value-based-care, payment-model] +processed_by: vida +processed_date: 2026-03-16 +enrichments_applied: ["value-based care transitions stall at the payment boundary because 60 percent of payments touch value metrics but only 14 percent bear full risk.md", "GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md", "glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md"] +extraction_model: "anthropic/claude-sonnet-4.5" --- ## Content @@ -50,3 +54,12 @@ CMS announced the Better Approaches to Lifestyle and Nutrition for Comprehensive PRIMARY CONNECTION: [[the healthcare attractor state is a prevention-first system where aligned payment continuous monitoring and AI-augmented care delivery create a flywheel that profits from health rather than sickness]] WHY ARCHIVED: First explicit federal test of the GLP-1 + VBC thesis — if it demonstrates net savings under risk-bearing, it validates the prevention-first attractor state; if it fails, it complicates it EXTRACTION HINT: Focus on the structural design (medication + lifestyle + payment adjustment) as a test of the attractor state thesis, not just as drug coverage policy + + +## Key Facts +- CMS BALANCE Model manufacturer RFA due January 8, 2026 +- Medicaid participation begins May 2026 +- Medicare Part D bridge demonstration begins July 2026 +- Full Medicare Part D participation begins January 2027 +- Model testing concludes December 2031 +- CMS negotiates drug pricing centrally on behalf of participating plans